These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37195585)

  • 1. Pelabresib (CPI-0610): An Exciting Novel Drug for the Treatment of Myelofibrosis.
    Ferreira Gomes G; Harrison C
    Curr Hematol Malig Rep; 2023 Aug; 18(4):113-120. PubMed ID: 37195585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
    Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
    Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis.
    Gupta V; Mascarenhas J; Kremyanskaya M; Rampal RK; Talpaz M; Kiladjian JJ; Vannucchi AM; Verstovsek S; Colak G; Dey D; Harrison C
    Blood Adv; 2023 Sep; 7(18):5421-5432. PubMed ID: 37530627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
    Mascarenhas J; Kremyanskaya M; Patriarca A; Palandri F; Devos T; Passamonti F; Rampal RK; Mead AJ; Hobbs G; Scandura JM; Talpaz M; Granacher N; Somervaille TCP; Hoffman R; Wondergem MJ; Salama ME; Colak G; Cui J; Kiladjian JJ; Vannucchi AM; Verstovsek S; Curto-García N; Harrison C; Gupta V
    J Clin Oncol; 2023 Nov; 41(32):4993-5004. PubMed ID: 36881782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis.
    Chifotides HT; Bose P; Masarova L; Pemmaraju N; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):210-223. PubMed ID: 34840087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
    Blum KA; Supko JG; Maris MB; Flinn IW; Goy A; Younes A; Bobba S; Senderowicz AM; Efuni S; Rippley R; Colak G; Trojer P; Abramson JS
    Cancer Res Commun; 2022 Aug; 2(8):795-805. PubMed ID: 36923307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
    Chen YY; Huang CE; Lee KD; Chen CC
    Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes.
    Mascarenhas JO; Verstovsek S
    Cancer; 2022 Jul; 128(14):2717-2727. PubMed ID: 35385124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
    Chifotides HT; Masarova L; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):219-231. PubMed ID: 36797153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next Generation Therapeutics for the Treatment of Myelofibrosis.
    Tremblay D; Mascarenhas J
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
    Tiribelli M; Morelli G; Bonifacio M
    Expert Opin Pharmacother; 2024 Apr; 25(6):743-754. PubMed ID: 38738513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.
    Tremblay D; Hoffman R
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):351-362. PubMed ID: 34875179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
    Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
    Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia in myelofibrosis: Current and emerging treatment options.
    Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
    Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the management of patients with myelofibrosis.
    Manea PJ
    Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Therapies for Myelofibrosis.
    Pettit K; Odenike O
    Curr Hematol Malig Rep; 2017 Dec; 12(6):611-624. PubMed ID: 29098608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ruxolitinib for myelofibrosis.
    Santos FP; Verstovsek S
    Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.